Adnectins: engineered target-binding protein therapeutics
about
Intracellular targeting with engineered proteinsApplications of Yeast Surface Display for Protein EngineeringHydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeuticsMonoclonal antibodies for the treatment of cancerTeaching an Old Scaffold New Tricks: Monobodies Constructed Using Alternative Surfaces of the FN3 ScaffoldSelection of Specific Protein Binders for Pre-Defined Targets from an Optimized Library of Artificial Helicoidal Repeat Proteins (alphaRep)Structural Similarity between Defense Peptide from Wheat and Scorpion Neurotoxin Permits Rational Functional DesignC-terminal β-strand swapping in a consensus-derived fibronectin Type III scaffoldA current perspective on applications of macrocyclic-peptide-based high-affinity ligandsExtremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein ScaffoldDerivative of Extremophilic 50S Ribosomal Protein L35Ae as an Alternative Protein ScaffoldUse of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Anti-idiotypic monobodies derived from a fibronectin scaffold.Engineering of monobody conjugates for human EphA2-specific optical imaging.Tetraspecific ligand for tumor-targeted delivery of nanomaterials.Structural basis of IL-23 antagonism by an Alphabody protein scaffoldPeptide aptamers: development and applications.The influence of adnectin binding on the extracellular domain of epidermal growth factor receptor.Epitope-guided engineering of monobody binders for in vivo inhibition of Erk-2 signaling.Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2.Small-molecule modulators of the constitutive androstane receptor.High-Throughput Ligand Discovery Reveals a Sitewise Gradient of Diversity in Broadly Evolved Hydrophilic Fibronectin DomainsStreamlining the Pipeline for Generation of Recombinant Affinity Reagents by Integrating the Affinity Maturation Step.A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering.ANTICALIgN: visualizing, editing and analyzing combined nucleotide and amino acid sequence alignments for combinatorial protein engineering.Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution.Titratable Avidity Reduction Enhances Affinity Discrimination in Mammalian Cellular Selections of Yeast-Displayed Ligands.Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.Circumventing the stability-function trade-off in an engineered FN3 domainAlternative Non-Antibody Protein Scaffolds for Molecular Imaging of CancerRECRUIT-TandAbs: harnessing the immune system to kill cancer cells.PCSK9 Inhibitors: potential in cardiovascular therapeutics.Design and evaluation of radiolabeled tracers for tumor imaging.Development of proteome-wide binding reagents for research and diagnostics.Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.The integration of ligand binding and LC-MS-based assays into bioanalytical strategies for protein analysis.Antibody mimetics: promising complementary agents to animal-sourced antibodies.
P2860
Q26740106-0A550B22-103D-4316-BABB-5DD8F6C51485Q26823830-944E9487-3019-49D2-A72C-A11E792AB9A2Q27004640-519E777F-0107-4D0C-A5BB-90CC017E78B0Q27025966-A672CF27-56B8-4FE6-96BA-A736EC9B0633Q27676439-06C7316F-9C6A-4444-B548-2414179F8EE3Q27679895-9861E705-449A-40A9-A11D-F9B3A6CD42C0Q27682550-E9092E64-D5A7-42CB-A9C1-81EECBDE0C9CQ27688045-9D4F3CBF-BE64-4236-AA7A-DE6F430B4C96Q28072407-65EC9733-060B-44DC-BAE5-2B6A651B5F39Q28547051-1303E810-310C-4FFD-B2FE-E174FF18576FQ28818769-066EF861-7B13-4CA5-A53B-768FF4A0BC8AQ30511916-A27BF6D9-FB2E-4A76-8D43-120A17D8A881Q33599961-D2FC97C7-D802-486C-BC5F-1A063C4B60BCQ33876210-EAF9E480-7048-4414-90D0-669A8E221CD3Q33884270-B695A636-4CBC-42B4-8ED9-A4256060531EQ34380877-85BF98F8-84F7-44BD-93C1-5A9F2332A87AQ34445379-14C71134-FB31-4DC1-B368-B0E465D36E27Q34471346-CF21A9DF-838F-4F72-89EE-FC7675846CDEQ34474034-451C63CD-89AF-41AB-9235-686DAF3C4AD9Q34507603-BC33E7B6-7654-4CCB-901E-5AF5503CBC45Q35692461-F3A3235C-16F6-4A1E-9CA2-F2E7AB499F0EQ35748820-37D91498-B6AB-4D0F-8E29-3FC2A67D9C02Q35780298-2E35DA28-9644-4CA3-9472-8FD85D652266Q35799445-F16C844C-54C6-4030-A932-C907D41696D4Q35954982-C11368CE-15A5-42DF-8E49-4E486C1E6E55Q36040901-D3C0A89B-BD16-4BD1-A785-34A7DCC4EDA7Q36254454-B54D2AA1-E3A0-40D3-A332-591842CF284FQ36316025-179F256B-3D93-4193-8346-8AA553B73D3BQ36333938-945DBFF0-3D83-47B1-9FBB-E0699FD2AD20Q36393594-D21721F1-F50A-4C0A-8899-FDB0E1216C49Q37367962-D9D78665-9DBF-4B17-834E-CA19E9657088Q37394193-7ECABF38-8BB1-421F-808E-68E55D30C43DQ38024123-B8E88F16-A5B1-4EEB-BB0B-7A18072641DDQ38075818-DFF8835C-3DB7-49EF-B747-6E2F74221D3DQ38137253-FE52248E-845F-4C31-ADBB-94AA0E7A880DQ38157763-A9A22A68-6EAA-4D18-9E7C-91D2381DB8D1Q38221015-CCF4C420-7208-4F15-A247-501E73E66989Q38236706-066DC693-338E-412D-A32D-58005FFCAC02Q38243344-96F5C4B7-F8BC-4202-8606-B30C097BD991Q38255176-ABE5F175-3354-4B29-B475-A236FAA7F3E8
P2860
Adnectins: engineered target-binding protein therapeutics
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Adnectins: engineered target-binding protein therapeutics
@ast
Adnectins: engineered target-binding protein therapeutics
@en
type
label
Adnectins: engineered target-binding protein therapeutics
@ast
Adnectins: engineered target-binding protein therapeutics
@en
prefLabel
Adnectins: engineered target-binding protein therapeutics
@ast
Adnectins: engineered target-binding protein therapeutics
@en
P2860
P921
P356
P1476
Adnectins: engineered target-binding protein therapeutics
@en
P2093
D Lipovsek
P275
P2860
P356
10.1093/PROTEIN/GZQ097
P577
2010-11-10T00:00:00Z
2011-01-01T00:00:00Z